CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Inhibitors, ACE +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000542
NCT00000542Phase 3Completed

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Jul 29, 2016

In Brief

A Phase 3 clinical trial evaluating Inhibitors, ACE, amlodipine, and 5 other interventions for Cardiovascular Diseases and 8 related conditions. Completed.

Detailed Summary

To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartAug 1, 1993
Primary CompletionMar 1, 2002
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 26.7 years ago

Interventions

Inhibitors, ACEdrug

amlodipinedrug

lisinoprildrug

doxazosindrug

chlorthalidonedrug

pravastatindrug

diet, fat-restrictedbehavioral